A hospital budget impact model to compare stem cell mobilisation strategies: impact of primary research and direct stakeholder engagement
I. Jensen(Aalborg University Hospital), Peter A. McSweeney(Mesoblast (United States)), Ronald J. Halbert, Giuseppe Rossi(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Sheikh Usman Iqbal, Zhimin Xiao, Sarah Naoshy(Sanofi (United States))
Cited by 2
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k